The General Manager of Chengdu New Radiomedicine Technology Co.,Ltd, Mr. Jiming Cai, and his team came to visit our office on Oct. 28th 2021 in Berlin. As one of the large medical isotope providers in China they expressed great interest in our new class of theranostic pharmaceuticals based on FAP inhibitor.
Our CEO, Prof. Dr. Rösch, presented the latest results for our new homodimer pharmaceuticals from our medical partners including systematic patient treatments for different tumor types, such as thyroid cancers, breast cancer, neuroendocrine tumors etc. After only 1-2 treatment cycles the size of tumor lesions was reduced and all patients experienced less pain and more mobility in the daily life. No patient showed serious adverse effects.
Mr. Cai showed enthusiasm for the clinical results, which were conducted to human-use for this first time in the world. The partners agreed to develop new pharmaceuticals with another radioisotope. We are looking forward to new projects and challenges in close collaboration with CNRT China.
